title: Predictors of short-term outcomes related to central subfield foveal thickness after intravitreal bevacizumab for macular edema due to central retinal vein occlusion.
abstract: OBJECTIVE
  To investigate the predictive factors for short-term effects of intravitreal bevacizumab injections on central subfield foveal thickness (CSFT) in patients with macular edema (ME) secondary to central retinal vein occlusion (CRVO).
  
  
  METHODS
  This was a retrospective study in 60 eyes treated with intravitreal bevacizumab injections for ME due to CRVO. Follow-up was three months. The Early Treatment Diabetic Retinopathy Study (ETDRS) score and CSFT measured by spectral-domain optical coherence tomography (SD-OCT) were used to observe the changes in best-corrected visual acuity (BCVA). Baseline BCVA, CSFT, age, CRVO duration and the presence of cystoid macular edema (CME) or subretinal fluid (SRF) were analyzed as potential predictive factors of the effects of intravitreal bevacizumab injections.
  
  
  RESULTS
  BCVA improved from 0.9 logMAR at baseline to 0.6 logMAR at 3mo, which was associated with a significant reduction in CSFT from 721 µm to 392 µm 3mo after injection. About 50% of CME cases and more than 90% of SRF cases responded to treatment with a complete resolution at 3mo. Age (P=0.036) and low baseline CSFT (P=0.037) were associated with a good 3-month prognosis. Patients >60 years old achieved better CME resolution (P=0.031) and lower CSFT at 3mo (305 µm vs 474 µm, P=0.003).
  
  
  CONCLUSIONS
  Intravitreal bevacizumab significantly improved visual acuity and CSFT in patients with CRVO after 3mo. Older age and lower baseline CSFT were good predictors of short-term CSFT outcomes. The retinal thickness response to bevacizumab might depend on the resolution of CME rather than SRF.
authors.affiliation: Department of Ophthalmology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China.
authors.forename: Mei-Zi
authors.initials: MZ
authors.lastname: Wang
authors.affiliation: Peking University Eye Center, Peking University Third Hospital, Key Laboratory of Vision Loss and Restoration, Ministry of Education, Beijing 100191, China.
authors.forename: Kang
authors.initials: K
authors.lastname: Feng
authors.affiliation: Peking University Eye Center, Peking University Third Hospital, Key Laboratory of Vision Loss and Restoration, Ministry of Education, Beijing 100191, China.
authors.forename: Yao
authors.initials: Y
authors.lastname: Lu
authors.affiliation: Peking University Eye Center, Peking University Third Hospital, Key Laboratory of Vision Loss and Restoration, Ministry of Education, Beijing 100191, China.
authors.forename: Fang
authors.initials: F
authors.lastname: Qian
authors.affiliation: Peking University Eye Center, Peking University Third Hospital, Key Laboratory of Vision Loss and Restoration, Ministry of Education, Beijing 100191, China.
authors.forename: Xin-Rong
authors.initials: XR
authors.lastname: Lu
authors.affiliation: Peking University Eye Center, Peking University Third Hospital, Key Laboratory of Vision Loss and Restoration, Ministry of Education, Beijing 100191, China.
authors.forename: Si-Wen
authors.initials: SW
authors.lastname: Zang
authors.affiliation: Peking University Eye Center, Peking University Third Hospital, Key Laboratory of Vision Loss and Restoration, Ministry of Education, Beijing 100191, China.
authors.forename: Lin
authors.initials: L
authors.lastname: Zhao
keywords: bevacizumab; central retinal vein; central subfield foveal thickness; intravitreal injection; macular edema